ArticleFood science & nutrition2026
Coix Seed Attenuates Acute Lung Injury via NLRP3 Signaling Pathway: Efficacy, Active Components, and Mechanisms.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coix seed is a medicinal and nutritional resource, but its protective effects against acute lung injury (ALI) remain unclear. This study investigated the efficacy, active components, and mechanisms of Coix seed extract (CSE) against ALI, focusing on the NLRP3 signaling pathway. The therapeutic efficacy of CSE was evaluated in a murine model of ALI. Liquid chromatography-mass spectrometry identified 32 components in CSE, which were then analyzed via network pharmacology, molecular docking, and molecular dynamics simulations for target prediction and drug-likeness evaluation. In vivo effects on NLRP3 pathway proteins were also examined. CSE decreased serum levels of TNF-α and IL-1β, pulmonary levels of IL-1β and IL-18, indicating systemic and local inflammatory suppression. Furthermore, CSE downregulated the expression of NLRP3, Caspase-1, and GSDMD-N in lung tissues, suggesting inhibition of NLRP3 inflammasome-driven pyroptosis. Network analysis screened 35 core targets and 4 NLRP3-related key targets involved in pathways regulating inflammation, proliferation, and oxidative stress. Molecular docking and dynamics simulations further corroborated the "component-target-disease" interactions within this network. Drug-likeness evaluation identified 12 promising compounds, including syringaldehyde, tangeretin, and eriodictyol. Collectively, these findings demonstrate that CSE alleviates ALI by suppressing both inflammation and pyroptosis through multiple pathways, with NLRP3 as a central mechanistic hub. The identification of bioactive compounds with favorable pharmacokinetic properties provides a chemical basis for quality control and supports potential application of CSE as a functional food ingredient in the management of pulmonary inflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.